Literature DB >> 30246507

Helicobacter pylori and non-alcoholic fatty liver disease: A new enigma?

Ahmed Abdel-Razik1, Nasser Mousa1, Walaa Shabana1, Mohamed Refaey2, Rania Elhelaly3, Rasha Elzehery3, Mostafa Abdelsalam4, Ayman Elgamal5, Mervat R Nassar5, Atef Abu El-Soud5, Ahmed S Seif6, Ahmed M Tawfik7, Niveen El-Wakeel8, Waleed Eldars8.   

Abstract

BACKGROUND AND AIM: The relationship between Helicobacter pylori (H. pylori) and nonalcoholic fatty liver disease (NAFLD) is a matter of debate. We achieved this prospective work to study whether H. pylori infection is a risk factor for NAFLD.
METHODS: A cohort multicenter pilot study of 369 adults without NAFLD at baseline was followed up for 2 years. Serum leptin, insulin, tumor necrosis factor-α, adiponectin, and interleukin-6 were measured using an enzyme-linked immunosorbent assay (ELISA). Homeostasis model assessment of insulin resistance (HOMA-IR) and leptin/adiponectin ratio (LAR) were calculated. Fecal H. pylori antigen was measured by ELISA. A total of 127 participants with H. pylori positive were treated and then followed up for 3 months.
RESULTS: Helicobacter pylori-positive patients (46.3%) were associated with an increase in IR, proinflammatory cytokines, C-reactive protein (CRP), LAR, NAFLD-liver fat score (NAFLD-LFS), and hepatic steatosis index (HSI) (all P < 0.01). Multivariate analysis of NAFLD according to HSI and NAFLD-LFS reported that presence of H. pylori, LAR, CRP, IL-6, smoking, and age (all P < 0.01) were independent risk factors for the presence of NAFLD. Multiple models adjusted for potential mediators or confounders such as metabolic, inflammatory, and biochemical factors were constructed. After therapy of H. pylori infection, there was a significant reduction in lipogenic profile, IR, leptin, LAR, CRP, proinflammatory cytokines, HSI, and NAFLD-LFS, as well as, increasing HDL.
CONCLUSION: Helicobacter pylori infection was related to an increased risk of NAFLD development, through increased markers of IR, inflammatory mediators, and lipid metabolism. Moreover, its eradication can recover these NAFLD risk factors.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  zzm321990Helicobacter pylorizzm321990; hepatic steatosis; insulin resistance; nonalcoholic fatty liver disease

Mesh:

Substances:

Year:  2018        PMID: 30246507     DOI: 10.1111/hel.12537

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  17 in total

1.  Prevalence and risk factors of Helicobacter pylori infection in Ningxia, China: comparison of two cross-sectional studies from 2017 and 2022.

Authors:  Yan Zhou; Yanhong Deng; Yanjie You; Xue Li; Di Zhang; Hailong Qi; Ruichun Shi; Li Yao; Yuanyuan Tang; Xiaofei Li; Linke Ma; Yanlin Li; Jun Liu; Yaning Feng; Xianmei Chen; Qian Hao; Xuemei Li; Yuzhen Li; Min Niu; Hengjun Gao; Feihu Bai; Shengjuan Hu
Journal:  Am J Transl Res       Date:  2022-09-15       Impact factor: 3.940

2.  Helicobacter pylori Infection and Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.

Authors:  Keyvan Heydari; Mohammad Yousefi; Reza Alizadeh-Navaei; Parisa Lotfi; Fateme Sheydaee; Maedeh Raei; Alireza Vahdatinia; Amirhossein Hessami; Sajjad Rafati; Mahmood Moosazadeh; Roya Ghasemian; Fatemeh Salehi; Haleh Massoudi; Fatemeh Ghaffari-Saravi; Sahar Rismantab
Journal:  Turk J Gastroenterol       Date:  2022-03       Impact factor: 1.555

Review 3.  Relationship between Helicobacter pylori infection and nonalcoholic fatty liver disease: What should we expect from a meta-analysis?

Authors:  Lin Wei; Hui-Guo Ding
Journal:  Medicine (Baltimore)       Date:  2021-08-06       Impact factor: 1.817

4.  Association between Helicobacter pylori infection and nonalcoholic fatty liver: A meta-analysis.

Authors:  Rongqiang Liu; Qiuli Liu; Ying He; Wenqing Shi; Qianhui Xu; Qing Yuan; Qi Lin; Biao Li; Lei Ye; Youlan Min; Peiwen Zhu; Yi Shao
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

5.  Associations between Helicobacter pylori with nonalcoholic fatty liver disease and other metabolic conditions in Guatemala.

Authors:  Christian S Alvarez; Andrea A Florio; Julia Butt; Alvaro Rivera-Andrade; María F Kroker-Lobos; Tim Waterboer; Maria Constanza Camargo; Neal D Freedman; Barry I Graubard; Mariana Lazo; Eliseo Guallar; John D Groopman; Manuel Ramírez-Zea; Katherine A McGlynn
Journal:  Helicobacter       Date:  2020-10-02       Impact factor: 5.182

6.  Helicobacter pylori infection may increase the severity of nonalcoholic fatty liver disease via promoting liver function damage, glycometabolism, lipid metabolism, inflammatory reaction and metabolic syndrome.

Authors:  Chen Chen; Caiyun Zhang; Xuelin Wang; Feijuan Zhang; Ze Zhang; Pengchai Ma; Shuzhi Feng
Journal:  Eur J Gastroenterol Hepatol       Date:  2020-07       Impact factor: 2.586

7.  Active Helicobacter pylori Infection is Independently Associated with Nonalcoholic Steatohepatitis in Morbidly Obese Patients.

Authors:  Michael Doulberis; Simone Srivastava; Stergios A Polyzos; Jannis Kountouras; Apostolis Papaefthymiou; Jolanta Klukowska-Rötzler; Annika Blank; Aristomenis K Exadaktylos; David S Srivastava
Journal:  J Clin Med       Date:  2020-03-30       Impact factor: 4.241

8.  Helicobacter pylori as an Initiating Factor of Complications in Patients With Cirrhosis: A Single-Center Observational Study.

Authors:  Ahmed Abdel-Razik; Nasser Mousa; Rania Elhelaly; Rasha Elzehery; Ahmad S Hasan; Mostafa Abdelsalam; Ahmed Salah Seif; Ahmed M Tawfik; Niveen El-Wakeel; Waleed Eldars
Journal:  Front Med (Lausanne)       Date:  2020-03-24

Review 9.  The interplay between Helicobacter pylori and gastrointestinal microbiota.

Authors:  Chieh-Chang Chen; Jyh-Ming Liou; Yi-Chia Lee; Tzu-Chan Hong; Emad M El-Omar; Ming-Shiang Wu
Journal:  Gut Microbes       Date:  2021 Jan-Dec

10.  Frequency and risk factors of non-alcoholic fatty liver disease in Helicobacter pylori-infected dyspeptic patients: A cross-sectional study.

Authors:  Basit Siddiqui; Muhammad Kamran; Shiyam Sunder Tikmani; Rabeea Azmat; Zain Mushtaq; Saad Bin Zafar; Muhammad Tahir Khan; Javed Yakoob; Zaigham Abbas
Journal:  SAGE Open Med       Date:  2021-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.